Catalyst Funds Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Catalyst Funds Management’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$79.9K	Buy	+23,500	New	+$79.7K	0.01%	508

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Aquamarine Financial George Town $1.37B AUM

Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $102M AUM

Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $25B AUM 18.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Catalyst Funds Management's ORMP Position: Q1 2026 in Review

Catalyst Funds Management opened a new position in Oramed Pharmaceuticals (ORMP) in Q1 2026: 23,500 shares worth $79.9K. The stake represents 0.01% of the portfolio and ranks #508 among its holdings.

64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

Catalyst Funds Management held 23,500 shares of Oramed Pharmaceuticals worth $79.9K as of Q1 2026.
Oramed Pharmaceuticals was a new Catalyst Funds Management position in Q1 2026.
Oramed Pharmaceuticals made up 0.01% of Catalyst Funds Management's portfolio in Q1 2026, its #508 holding.
64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Catalyst Funds Management's 13F filing for Q1 2026, filed 11 May 2026.